TTNT and second primary malignancy incidence. (A) TTNT, defined as time to initiation of next line of antileukemic treatment or death from any cause, according to Ven-Obi (blue) or Clb-Obi (red) arm. (B) TTNT according to presence (solid line) or absence (dashed line) of TP53 deletion/mutation. (C) TTNT according to mutated- (solid line) and unmutated- (dashed line) IGHV status. (D) Cumulative incidence of SPM according to Ven-Obi (blue) and Clb-Obi (red) arm.